1Olapade - Olaopa EO, Morley RN, Carter C J, et al. Diabetic cystopathy presenting as primary acute urinary retention in a previously undiagnosed young male diabetic patient. J Diabetes Complications, 1997 ,11(6) :350 -351.
3Menendez V, Cofan F, Talbot - Wright R, et al. Urodynamic evaluation in simultaneous insulin - dependent diabetes mellitus and end stage renal disease. J Urol, 1996 , 155 ( 6 ) :2001 - 2004.
4Hampel C, Gillitzer R, Pahernik, et al. Diabetes mellitus and bladder function. What should be considered? Urologe A,2003 ,42(12) : 1556 - 1563.
5Sima AA, Sugimoto K. Experimental diabetic neuropathy: an update. Diabetologia, 1999,42 ( 7 ) :773 - 788.
6Asano T, Saito Y, Kawakami M, et al. Clinical Pharmacology Study Group. Erythrocytic sorbitol contents in diabetic patients correlate with blood aldose reductase protein contents and plasma glucose level, and are normalized by the potent aldose reductase inhibitor fidarestat (SNK - 860). J Diabetes Complications,2004,18 (6) :336 - 342.
7Hotta N, Akanuma Y, Kawamori R, et al.Long- term clinical effects of epalrestat, an aldose reduetase inhibitor, on diabetic peripheral neuropathy: the 3 -year, muhieenter, comparative Aldose Reduetase Inhibitor - Diabetes Complications Trial. Diabetes Care, 2006,29(7) :1538 - 1544.
8Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes,2005,54(6) :1615 - 1625.
9Bernard C. Steinbacher Jr. , Irving Nadelhaft. Increased levels of nerve growth factor in urinary bladder and hypertrophy of dorsal root ganglion neurons in the diabetic rat. Brain Research, 1998,782(1 - 2) :255 -260.
10Tong YC, Cheng JT. Changes in bladder nerve - growth factor and p75 genetic expression in streptozotocin - induced diabetic rats. BJU Int. 2005,96(9) :1392 - 1396.
